MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.520
+0.030
+2.01%
After Hours: 1.530 +0.01 +0.66% 19:04 01/09 EST
OPEN
1.500
PREV CLOSE
1.490
HIGH
1.540
LOW
1.480
VOLUME
2.65M
TURNOVER
--
52 WEEK HIGH
4.079
52 WEEK LOW
1.445
MARKET CAP
403.36M
P/E (TTM)
-20.0000
1D
5D
1M
3M
1Y
5Y
1D
Akebia Doses First Patient In Phase 2 Study Of Praliciguat For Rare Kidney Disease
NASDAQ · 4d ago
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
TipRanks · 4d ago
Akebia announces first patient dosed in Phase 2 trial of praliciguat
TipRanks · 5d ago
Akebia Therapeutics Doses First Participant In Phase 2 Clinical Study Of Praliciguat To Treat Biopsy-Confirmed Focal Segmental Glomerulosclerosis
Benzinga · 5d ago
Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS
Reuters · 5d ago
AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Reuters · 5d ago
Akebia Therapeutics Grants Stock Options to New Employee at $1.61 Per Share
Reuters · 6d ago
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.